EarningsQ2 2026 Earnings Report
DE:CUP Q2 2026 EPS Results
Actual EPS€0.38
Consensus EPS€0.42
Beat/MissMissed by -€0.04
One Year Ago EPS€0.32
DE:CUP Q2 2026 Revenue Results
Actual Revenue€1.91B
Expected Revenue€1.90B
Beat/MissBeat by +€10.00M
YoY Revenue Growth+17.79%
Earnings Announcement Details
QuarterQ2 2026
Date07/24/2026
TimeBefore Open
Conference CallFriday, July 24, 2026
DE:CUP Upcoming Earnings
Chugai Pharmaceutical Co's next earnings date is estimated for October 27, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:CUP Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong financial performance (material YoY increases in revenue, operating profit and net income), robust product sales growth, multiple clinical and regulatory milestones (Phase III starts, positive readouts, orphan designations, FDA Fast Track for AQUA07) and a disciplined capital allocation stance with continued dividend increases. Headwinds include pricing pressure from NHI revisions and generic competition for legacy products, some cost increases, visibility challenges around partner royalty timing (notably NEMLUVIO), and uncertainty from international pricing policy changes. On balance, the positive operational and pipeline progress and solid financials outweigh the negatives.Company Guidance
Strong Revenue Growth
First-half revenue of JPY 663.3 billion, up JPY 84.8 billion or 14.7% year‑on‑year, driven by increases across domestic, overseas and other revenue.
Robust Profitability Expansion
Core operating profit rose to JPY 329.1 billion, up JPY 57.1 billion or 21.0% YoY; operating margin improved by 2.6 percentage points to 49.6%.
Net Income Improvement
Net income after tax of JPY 238.4 billion, up JPY 44.9 billion or 23.2% YoY, aided by improved net financial income and higher interest rates.
Product Sales Growth
Product sales totaled JPY 566.5 billion, an increase of JPY 55.1 billion or 10.8% YoY; overseas product sales grew JPY 40.5 billion (+14.1% YoY) and domestic product sales increased JPY 14.6 billion (+6.5% YoY).
Other Revenue Jump from Royalties and One-Time Income
Other revenue rose to JPY 96.8 billion, an increase of JPY 29.8 billion YoY, reflecting significant one‑time income and higher royalty income (notably from Hemlibra and NEMLUVIO) and recognition of Foundayo royalty revenue starting in Q2.
Pipeline Advancements and Regulatory Filings
Eight regulatory applications filed in Japan (with total filings for 2026 expected to reach ~16 across regions), including filings for Gazyva, giredestrant, Tecentriq (esophageal cancer), sparsentan and port delivery platform components.
NXT007 and Late‑Stage Development Progress
Initiation of two Phase III studies for NXT007 (zemocimig) in hemophilia A, positioning it as a potential next‑generation growth driver.
AQUA07 First Patient Dosed and FDA Fast Track
AQUA07 (macrocyclic peptide allosteric ALK inhibitor) dosed first patient in clinical study and received U.S. FDA Fast Track designation (May 2026), supporting development as a novel option to address ALK inhibitor resistance and combination strategies.
Positive Clinical Readouts
Phase III divarasib in second‑line NSCLC met its primary endpoint; AVMAPKI Phase Ib/IIa in metastatic pancreatic ductal adenocarcinoma showed 52% overall response rate among 29 evaluable patients.
PiaSky Phase III Success and Filing Plans
PiaSky COMMUTE‑a complete remission rate 59.5% (exceeding 40% success criteria); COMMUTE‑p remission 17.6%; remission maintenance rate 100% for switchers; dialysis‑dependent patients discontinued dialysis. Plans to file in Japan, U.S. and Europe within the year.
Other R&D Milestones and Orphan Designations
REVN24 achieved biological POC in Phase I and is preparing for Phase II; third macrocyclic peptide project (AQUA07) advanced; zemocimig, vamikibart and Gazyva received orphan drug designations.
Capital Allocation and Shareholder Returns
Strategic Investment Department established to pursue M&A/in‑licensing and other growth investments; stable dividend policy with expected annual dividend of JPY 132 per share and 10th consecutive ordinary dividend increase (special dividend paid this period).
Strong Balance Sheet Metrics
Equity ratio improved to 82.8%; net cash remains high at JPY 962.6 billion despite a decrease of JPY 70.1 billion (post special dividend and tax payments).
DE:CUP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed